PEDF effectively decreases VEGF to PEDF messenger RNA ratio of the inner edge of rat hepatocellular carcinoma induced by diethyl nitrosamine - An "In Vivo" Study

Hepato-Gastroenterology

Volumn 59, Issue 117, 2012, Pages 1484-1490

  Jeng, Kuo Shyang ^a   Sheen, I Shyan ^b   Jeng, Wen Juei ^b   Su, Jui Chih ^a  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Hepatocellular carcinoma; Pigment epithelium derived factor; Vascular endothelial growth factor

Indexed keywords

DIETHYLNITROSAMINE; MESSENGER RNA; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VOLUME;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DIETHYLNITROSAMINE; EYE PROTEINS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NERVE GROWTH FACTORS; RATS; RATS, INBRED LEW; RNA, MESSENGER; SERPINS; STATISTICS, NONPARAMETRIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865197585     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11543     Document Type: Article

References (39)

1. Jeng KS, Sheen IS, Wang YC, et al.: Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection? World J Gastroenterol 2004; 10:676-681.
2. Ferroni P, Spila A, D'Alessandro R, et al.: Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer. Clin Chim Acta 2011; 412:450-454.
3. Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49:407-424.
4. Suzuki K, Hayashi N, Miyamoto Y, et al.: Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 1996; 56:3004-3009.
5. Mise M, Arii S, Higashituji H, et al.: Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996; 23:455-464.
6. Miura H, Miyazaki T, Kuroda M, et al.: Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 1997; 27:854-861.
7. Jinno K, Tanimizu M, Hyodo I, et al.: Circulating vascular endot helial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 1998; 33:376-382.
8. Torimura T, Sata M, Ueno T, et al.: Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998; 29:986-991.
9. Yoshiji H, Kuriyama S, Yoshii J, et al.: Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 1998; 28:1489-1496.
10. Ponsuksili S, Murani E, Schellander K, Schwerin M, Wimmers K: Identification of functional candidate genes for body composition by expression analyses and evidencing impact by association analysis and mapping. Biochim Biophys Acta 2005; 1730:31-40.
11. Sawant S, Aparicio S, Tink AR, Lara N, Barnstable CJ, Tombran-Tink J: Regulation of factors controlling angiogenesis in liver development: a role for PEDF in the formation and maintenance of normal vasculature. Biochem Biophys Res Commun 2004; 325:408-413.
12. Manalo KB, Choong PF, Dass CR: Pigment epithelium-derived factor as an impending therapeutic agent against vascular epithelial growth factor-driven tumor-angiogenesis. Mol Carcinog 2011; 50:67-72.
13. Feng CC, Ding Q, Zhang YF, et al.: Pigment epithelium-derived factor expression is down-regulated in bladder tumors and correlates with vascular endothelial growth factor and matrix metalloproteinase-9. Int Urol Nephrol 2011; 43:383.
14. Bhadada SV, Goyal BR, Patel MM: Angiogenic targets for potential disorders. Fundam Clin Pharmacol 2011; 25:29-47.
15. Ishikawa H, Nakao K, Matsumoto K, et al.: Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene. Hepatology 2003; 37:696-704.
16. Chen JF, Zhao W, Zhang JZ, Jiang WG, Zhang LJ: Effects of pigment epithelial derived factor gene on growth of lung cancer cell and neovascularization: experiments with lung cancer cells and chick embryos. Zhonghua Yi Xue Za Zhi 2009; 89:485-490.
17. Yang H, Cheng R, Liu G, et al.: PEDF inhibits growth of retinoblastoma by anti-angiogenic activity. Cancer Sci 2009; 100:2419-2425.
18. Broadhead ML, Dass CR, Choong PF: In vitro and in vivo biological activity of PEDF against a range of tumors. Expert Opin Ther Targets 2009; 13:1429-1438.
19. Kawaguchi T, Yamagishi S, Itou M, et al.: Pigment epithelium-derived factor inhibits lysosomal degradation of Bcl-xL and apoptosis in HepG2 cells. Am J Pathol 2010; 176:168-176.
20. Gao Y, Zhang W, Zhao L, Wang XH: Pigment epithelium-derived factor gene therapy inhibits the growth of transplanted human hepatocellular carcinoma in nude mice. Zhonghua Gan Zang Bing Za Zhi 2009; 17:363-367.
21. Broadhead ML, Dass CR, Choong PF: Cancer cell apoptotic pathways mediated by PEDF: prospects for therapy. Trends Mol Med 2009; 15:461-467.
22. Zhou D, Cheng SQ, Ji HF, et al.: Evaluation of protein pigment epithelium-derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer. J Cancer Res Clin Oncol 2010; 136:1719-1727.
23. Dass CR, Ek ET, Choong PF: PEDF as an emerging therapeutic candidate for osteosarcoma. Curr Cancer Drug Targets 2008; 8:683-690.
24. Broadhead ML, Akiyama T, Choong PF, Dass CR: The pathophysiological role of PEDF in bone diseases. Curr Mol Med 2010; 10:296-301.
25. Filleur S, Volz K, Nelius T, et al.: Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 2005; 65:5144-5152
26. Cui FY, Song XR, Li ZY, et al.: The pigment epithelial-derived factor gene loaded in PLGA nanoparticles for therapy of colon carcinoma. Oncol Rep 2010; 24:661-668.
27. Murray AR, Ma JX: PEDF as a treatment for cervical cancer. Cancer Biol Ther 2010; 9:975-977.
28. Chen J, Ye L, Zhang L, Jiang WG: The molecular impact of pigment epithelium-derived factor, PEDF, on lung cancer cells and the clinical significance. Int J Oncol 2009; 35:159-166.
29. Fan W, Crawford R, Xiao Y: The ratio of VEGF/PEDF expression in bone marrow mesenchymal stem cells regulates neovascularization. Differentiation 2011; 81:181-191.
30. Li CM, Li W, Man XY, et al.: Pigment epithelium-derived factor plays an inhibitory role in proliferation and migration of HaCaT cells. Mol Biol Rep 2011; 38:2099-2105.
31. Feng CC, Wang PH, Ding Q, et al.: Expression of pigment epithelium-derived factor and tumor necrosis factor-α is correlated in bladder tumor and is related to tumor angiogenesis. Urol Oncol 2011.
32. Yang J, Chen S, Huang X, et al.: Growth suppression of cervical carcinoma by pigment epithelium-derived factor via anti-angiogenesis. Cancer Biol Ther 2010; 9:967-974.
33. Zhang Y, Han J, Yang X, et al.: Pigment epithelium-derived factor inhibits angiogenesis and growth of gastric carcinoma by down-regulation of VEGF. Oncol Rep 2011; 26:681-686.
34. van Zijl F, Mair M, Csiszar A, et al.: Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009; 28:4022-4033.
35. Kuang DM, Zhao Q, Wu Y, et al.: Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011; 54:948-955.
36. Giannelli G, Bergamini C, Marinosci F, et al.: Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002; 97:425-431.
37. Giannelli G, Fransvea E, Bergamini C, Marinosci F, Antonaci S: Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin Cancer Res 2003; 9:3684-3691.
38. Matsunaga Y, Koda M, Murawaki Y: Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue. Res Commun Mol Pathol Pharmacol 2004; 115-116:143-150.
39. Hirsch J, Johnson CL, Nelius T, Kennedy R, Riese W, Filleur S: PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFκB and PPARγ. Cytokine 2011; 55:202-210.